<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356161</url>
  </required_header>
  <id_info>
    <org_study_id>CVK-HAI 1</org_study_id>
    <nct_id>NCT00356161</nct_id>
  </id_info>
  <brief_title>HAI Via Interventionally Implanted Port Catheter Systems</brief_title>
  <official_title>Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <brief_summary>
    <textblock>
      Procedures to provide interventional implantation of a port catheter system into the hepatic&#xD;
      artery and adjacent regional chemotherapy of the liver are optimized in the scope of an open,&#xD;
      single-arm trial in patients with metastases and cancers confined to the liver. The primary&#xD;
      objective is the improvement of indication, implantation procedure, and regional&#xD;
      chemotherapy. Secondary objectives are port patency, comparison of complications with a&#xD;
      historical collective of patients provided with a surgical hepatic arterial port device&#xD;
      (colorectal cancer patients only), progression free and overall survival, efficacy of&#xD;
      maintaining regional chemotherapy with 5-FU in combination with systemic treatment in&#xD;
      patients with extrahepatic progression, quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:&#xD;
&#xD;
        -  histologically confirmed hepatic cancer without symptomatic extrahepatic manifestation.&#xD;
&#xD;
        -  non-resectable disease or hepatic resection or ablation in between the past 8 weeks.&#xD;
&#xD;
        -  measurable disease (at least before hepatic resection)&#xD;
&#xD;
        -  Karnofsky performance status =&gt; 70%, or ECOG status 0-2&#xD;
&#xD;
        -  &gt;18 years of age&#xD;
&#xD;
        -  life expectancy &gt; 6 months&#xD;
&#xD;
        -  compliance of the patient&#xD;
&#xD;
        -  written informed consent&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  second neoplasia within the past 3 years, except for non-melanotic skin cancer,&#xD;
           adequately treated Ca in situ of cervix uteri, or adequately resected second colorectal&#xD;
           cancer (in patients with liver metastases of colorectal cancer)&#xD;
&#xD;
        -  symptomatic extrahepatic disease, in particular disseminated bone metastases, brain&#xD;
           metastases&#xD;
&#xD;
        -  liver cirrhosis with portal hypertension, active hepatitis B or C, previous percutaneous&#xD;
           radiotherapy of the liver&#xD;
&#xD;
        -  active infection&#xD;
&#xD;
        -  history of gastric or duodenal ulcer&#xD;
&#xD;
        -  symptomatic or uncontrolled peripheral arterial occlusive disease, history of stenosis&#xD;
           of the renal artery.&#xD;
&#xD;
        -  history of dilatative cardiomyopathy, vitium of mitral or aortic valve, persisting&#xD;
           foramen ovale, atrial fibrillation&#xD;
&#xD;
        -  artificial heart valve or vascular&#xD;
&#xD;
        -  history of diabetic microangiopathy&#xD;
&#xD;
        -  uncontrolled hyperthyriodism&#xD;
&#xD;
        -  other severe concomitant disease (heart failure &gt;NYHA 2°, respiratory failure, renal&#xD;
           failure &gt;stage2, liver failure (TPZ &lt;50%).&#xD;
&#xD;
        -  inherited or acquired immunodeficiency syndrome&#xD;
&#xD;
        -  contraindication against 5-FU&#xD;
&#xD;
        -  pregnancy and nursing, no contraception&#xD;
&#xD;
        -  limited contractual capability.&#xD;
&#xD;
      After enrollment, an a port catheter catheter system is interventionally implanted into the&#xD;
      hepatic artery and the patient is scheduled for regional chemotherapy according one out of 8&#xD;
      pre-defined chemotherapy schedules. All regimens are based on 5-fluorouracil and leucovorin,&#xD;
      and optionally contain intraarterial mitomycin, oxaliplatin, or additional intravenous&#xD;
      irinotecan.&#xD;
&#xD;
      Patients are followed up and evaluated for primary and secondary endpoints. After the&#xD;
      inclusion of 50 patients treated and follow up at our institution, the study population has&#xD;
      been extended to 100 patients in 8/2004.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2002</start_date>
  <completion_date>April 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of evaluation and intervention group</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Complication rate (device implantation)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of device and regional therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>prospective evaluation of port duration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of complication and port duration with an historical collective of patients provided with a surgically implanted hepatic arterial port catheter system (liver metastases of colorectal cancer)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free and overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy of maintaining regional therapy combined with systemic chemotherapy in patients with extrahepatic progression while on study</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
  </secondary_outcome>
  <enrollment>100</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Neoplasms</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Gallbladder Cancer</condition>
  <condition>Bile Duct Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>interventionally implanted hepatic arterial port catheter</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        see above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        see above&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bert Hildebrandt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Charté Centrum Tumormedizin, CVK, D-13344 Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanno Riess, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Charité Centrum Tumormedizin, CVK, D-13344 Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Ricke, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinik für Radiologie und Nuklearmedizin, Universität Magdeburg, Leipziger Str. 44, D-39120 Magdeburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roland Felix, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinik für Strahlenheilkunde, CVK, Charité Universitätsmedizin Berlin, D-13344 Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Neuhaus, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Charité Centrum Chirurgische Medizin, CVK, D-13344 Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bert Hildebrandt, MD</last_name>
    <phone>++49 30 450 553636</phone>
    <email>bert.hildebrandt@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanno Riess, MD, PhD</last_name>
    <phone>++49 30 450 553112</phone>
    <email>hanno.riess@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Centrum Tumormedizin, Medizinische Klinik für Hämatologie und Onkologie, CVK</name>
      <address>
        <city>Berlin</city>
        <zip>13344</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bert Hildebrandt, MD</last_name>
      <phone>++49 30 450 553 636</phone>
      <email>bert.hildebrandt@charite.de</email>
    </contact>
    <investigator>
      <last_name>Annett Nicolaou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maciej Pech, MD</last_name>
      <phone>+49 391 67-13030</phone>
      <email>radiologie@uni-magdeburg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Ricke J, Hildebrandt B, Miersch A, Nicolaou A, Warschewske G, Teichgräber U, Lopez Hänninen E, Riess H, Felix R. Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events. J Vasc Interv Radiol. 2004 Aug;15(8):825-33.</citation>
    <PMID>15297586</PMID>
  </reference>
  <verification_date>July 2006</verification_date>
  <study_first_submitted>July 24, 2006</study_first_submitted>
  <study_first_submitted_qc>July 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2006</study_first_posted>
  <last_update_submitted>July 24, 2006</last_update_submitted>
  <last_update_submitted_qc>July 24, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2006</last_update_posted>
  <keyword>colorectal neoplasms</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>gallbladder cancer</keyword>
  <keyword>bile duct cancer</keyword>
  <keyword>hepatic arterial infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

